Putney Receives Approval for Generic of Tresaderm
July 29, 2015
Portland, ME—July 29, 2015—Putney, Inc., a rapidly growing pet pharmaceutical company focused on the development and sale of generic prescription medicines for pets, has received FDA approval for its Thiabendazole, Dexamethasone, Neomycin Sulfate Solution, the first and only generic of Tresaderm®. This is Putney’s sixth first-to-market generic and its seventh new product approval in the last ten months. Putney’s Thiabendazole, Dexamethasone, Neomycin Sulfate Solution will be commercially available as soon as inventory levels are sufficient to meet anticipated high demand.
Putney’s Senior Vice President of Scientific and Medical Affairs, Dr. Anthony Lucas, BVMS, PhD, says Putney’s generic of Tresaderm is the latest addition to Putney’s ever-growing portfolio. “We’re developing the pet medicines that veterinarians and pet owners want most—FDA approved generics of the expensive brand medicines that they already use. Prescribing Putney’s affordable generics is an easy decision for veterinarians who want to improve practice profitability and provide pet owners with savings too,” says Dr. Lucas.
Jean Hoffman, Putney’s president and CEO, says the string of product approvals is a direct result of Putney’s significant investment in R&D. “Thiabendazole, Dexamethasone, Neomycin Sulfate Solution is a complicated product to develop and this approval is a credit to our R&D team. We are the leading pet generic company in the United States, in part, because we are developing the generics that no other company has been able to,” says Hoffman.
For the full story and more about Putney, click here.